Recent Articles
Recent Conferences
  2000
  1999

Basic Facts  >
Clinical Trial Hotline 
>

Co-infection with hepatitis among people with HIV is emerging as a growing problem. For people infected with HIV through needle exposure probably due to drug use, 40% or more may also have hepatitis C. The NATAP Hepatitis Section was started to raise awareness about this problem, and to provide basic education and more advanced scientific information.

If you have HIV you should speak to your doctor about testing for hepatitis A, B, and C. A person with hepatitis C may progress more quickly if they contract hepatitis A. If you have hepatitis C, but don't have hepatitis A, it's advisable to consider getting the hepatitis A vaccine.

As we report important information from key AIDS conferences, NATAP will be reporting important information presented at key hepatitis scientific conferences. They are posted below. Treatment guidelines presented by the European Association for The Study of Liver Disease at a consensus conference are posted below. NATAP will also be reporting new information from future key hepatitis conferences.

     2000
DECEMBER
Open-Label Pilot Study of the Safety and Efficacy of Adefovir Dipivoxil in HBV/HIV Coinfected Patients with 3TC Resistant HBV   (12/27/2000)

Hepatitis C New Drug Research & Development   (12/18/2000)

Treating HCV/HIV Coinfection: adherence, tolerability & response
(12/18/2000)

New Study Suggests Ribivarin Works By Causing Mutations with (PDF of full report) (12/16/2000)

Schering-Plough Submits Supplemental NDA to Market REBETOL(R)  (Ribavirin, USP) Capsules Separately for use in Combination Therapy for  Chronic Hepatitis C
    
Press Release from Schering-Plough, with introduction by Jules Levin

(12/14/2000)

Conquering Hepatitis C, Step by Step
    
Daniel F. Schafer, M.D., Michael F. Sorrell, M.D.( University of Nebraska Medical Center, Omaha, NE 68198) for The New England Journal of Medicine -- December 7, 2000 -- Vol. 343, No. 23

(12/14/2000)

Peginterferon alfa-2a in Chronic HCV & Cirrhosis, or Bridging Fibrosis
     New England Journal of Medicine, December 2000
 
(12/13/2000)

Protease Inhibitor Use & ALT Elevations
Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients
  (12/7/2000)

 Incidence and risk factors of statin or fibrate-induced hepatitis and myositis in HIV-infected patients  (12/6/2000)

Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C (12/4/2000)
Complete report in  PDF version .

Lactic Elevations & Mitochondrial Toxicity in HIV and Hepatitis C:
Should lactate levels be monitored in coinfected individuals?  (12/1/2000)

NOVEMBER
Can Persons With Decompensated Cirrhosis Be Treated for HCV?  (11/29/2000)

HCV, HAART, & Diabetes
What is the Association Between Diabetes & HCV & HAART?  (11/28/2000)

Interferon Alfacon-1 Induction Therapy: A Multicenter Trial in Subjects with Chronic Hepatitis C Virus Infection  (11/26/2000)

HCV/HIV Coinfected have more viral diversity than HCV infected; CD4s May Be Key in Immune Control  (11/26/2000)
HCV Quasispecies as a Mechanism of Rapidly Progress Liver Disease in Patients Infected with the Human Immunodeficiency Virus

Liver Cells May Die More Quickly in HIV/HCV Coinfection (DDW, May 2000)
Effect of Hepatitis C Virus & HIV-1 on Hepatic Parenchymal & Mononuclear Cell Proliferation and Apoptosis  (11/26/2000)

Does HIV Impair Immune Response to HCV? (11/25/2000)
Coinfected patients mount broad & strong response to HIV but not HCV.

Mitochondrial Abnormalities in HCV and HCV/HIV Coinfection
(11/25/2000)

Weight Reduction May Improve Fibrosis, ALT, Insulin & Triglycerides in Chronic HCV  (11/22/2000)

18 Months Interferon+Ribivarin Reduces Relapse Rate Compared to 6 Months Treatment (11/22/2000)

INTERFERON RESISTANCE:
Hepatitis C Virus Resistance to Antiviral Therapy  
(11/19/2000)
in PDF format 
   
By Jean Michel Pawlotsky

Grading and Staging the Histopathological Lesions of Chronic Hepatitis: The Knodell Histology Activity Index and Beyond (11/19/2000)
     by Elizabeth M. Brunt, St. Louis Univ. Hosp. (Hepatology, Jan 2000, p.241)
  
in PDF version ONLY  

Summary of 1 Day Conference Held at NIH in December 1999 entitled "Hepatitis C in African-Americans" (11/19/2000)
    (excerpted from Gastroenterology 2000; 119: 1385-1396)
       PDF version of entire article  

Resting Energy Expenditure In Chronic Hepatitis C  (11/19/2000)

Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels  (11/19/2000)

Highlights of AASLD Postgraduate Course
     Written by Marion Peters, MD, UCSF Chief of Hepatology Research, contributions by Jules Levin
(11/19/2000)

Summary of the AASLD Meeting - Hepatology, October 2000 supplement
 
    Written for NATAP by Ray Chung, MD, Director of Transplantation, Massachusetts General Hospital, Boston
(11/19/2000)

Watchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C
   Wong JB, Koff RS New England Medical Center, 750 Washington Street, Box 302, Boston, MA 02111.
(11/19/2000)

Effect of pregnancy on chronic hepatitis C: a case-control study (11/17/2000)

How soon can a virological sustained response be determined after withdrawal of interferon therapy in chronic hepatitis C? (11/09/2000)
  
Reported for NATAP by Tokyo-Chiba Hepatitis Research Group. Shiratori Y, Kato N, Yoshida H, Imazeki F, Okano K, Yokosuka O, Omata M Department of Internal Medicine (II), University of Tokyo, Japan. J Gastroenterol Hepatol 1999 Jan;14(1):79-84

OCTOBER

Effects of interferon treatment on the antiviral T-cell response in  hepatitis C virus genotype 1b- and genotype 2c-infected patients (10/3/2000)

Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings (10/3/2000)

SEPTEMBER

STRATEGIES FOR THE MANAGEMENT OF HCV/HIV COINFECTION: monograph intended to improve clinical skills of ID doctors and other care providers who treat persons with HIV and hepatitis C (9/11/2000)

Does Genotype Play Role In HCV Progression? (9/8/2000)

AUGUST

Maxim and Roche Expect Collaboration to Lead to Important Advances in the Treatment of Cancer and Hepatitis C (8/22/2000)

JULY

Follow-up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: the role of breast-feeding in transmission (7/28/2000)

Long-Term Follow-up of Interferon Therapy up to 10 years after achieving sustained undetectable HCV-RNA (7/28/2000)

Detection of hepatitis C virus in the semen of infected men, Lancet 2000 (7/20/2000)

IRON REDUCTION & INTERFERON THERAPY (7/5/2000)

JUNE
Fatty Liver By Howard Worman, M.D. (Fatty liver is called steatosis) (6/5/2000)
A Review of Two Studies on Hepatotoxicity and HIV Antiretroviral Drugs (6/5/2000)
FATTY LIVER in HCV/HIV Coinfection (6/5/2000)
Liver Fibrosis Progression in Human Immunodeficiency Virus and Hepatitis C Virus Coinfected Patients (6/5/2000)

Randomized Controlled Trial of Interferon Treatment for Advanced Hepatocellular Carcinoma (5/3/2000)

MAY
Maxamine for Hepatitis C Treatment (5/15/2000)  
Anti-Hepatitis C Ribozyme Completes Normal Volunteer Safety Study, Enters Clinical Trials in Chronic Hepatitis C Patients (5/11/2000)
Hepatic iron and nonalcoholic fatty liver disease (5/9/2000)  
APRIL
Liver-Specific Alpha 2 Interferon Gene Expression Results in Protection from Induced Hepatitis (4/29/2000)  
U.S. Food and Drug Administration Grants Expedited Review To Roche for First PCR-Based Tests to Detect Hepatitis C Virus (4/19/2000)
Hepatic Fibrosis Regresses in Interferon-Responsive Hepatitis C Patients (4/17/2000)  
STUDY SUGGESTS LOSS OF HEPATITIS B ANTIGEN INCREASES WITH LENGTH OF TREATMENT WITH EPIVIR-HBV (4/17/2000)  
Long-Term Incidence of Hepatitis B Virus Resistance to Lamivudine in Human Immunodeficiency Virus-Infected Patients (4/17/2000)  
Interferon in HBV/HIV Coinfection; Serum Alanine Transaminase Level Is a Good Predictor of Response to Interferon Alfa Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus-Infected Patients (4/17/2000)  
Natural History of Hepatitis C Virus Carriers With Persistently Normal Aminotransferase Levels (4/3/2000)  
Hepatitis C Immunology (4/3/2000)  
Host genetic factors influence disease progression in chronic hepatitis C (4/3/2000)  
Interleukin 10 Treatment Reduces Fibrosis in Patients With  Chronic Hepatitis C: A Pilot Trial of Interferon Nonresponders (4/3/2000)  
MARCH
Hepatitis C Transmission and Pregnancy (3/29/2000)  
New HCV Treatment in Early Development--Ribozymes; Inhibition of Hepatitis C Virus (HCV)-RNA-Dependent Translation and Replication of a Chimeric HCV Poliovirus Using Synthetic Stabilized Ribozymes (3/20/2000)
Transmission Rate of HCV to Newborn 5%; Prevalence and Clinical Course of Chronic Hepatitis C Virus (HCV) Infection and Rate of HCV Vertical Transmission in a Cohort of 15,250 Pregnant Women (3/20/2000)
          CTLs and Response to HCV Therapy (3/20/2000)
Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years;  Improved Fibrosis Seen with Long-Term treatment (>1 year) in Cirrhotic Patients in IFN Non-Responders (3/5/2000)
FEBRUARY
Hepatitis B Genotypes Correlate With Clinical Outcomes in Patients With Chronic Hepatitis B (2/14/2000)
Ongoing New Infection?: Detection of Circular Viral DNA in PBMC of HIV-Infected Individuals with No Detectable Viral RNA. (2/14/2000)
Race and Gender Issues: Conference on Viral Hepatitis, Maui, Dec 1999 (2/14/2000)
SERUM HCV-RNA, ALT LEVELS AND AST/ALT RATIO DO NOT PREDICT SEVERITY OF LIVER DISEASE IN CHRONIC HEPATITIS C VIRUS INFECTION (2/14/2000)
JANUARY
Amantadine and Rimantadine Have No Direct Inhibitory Effects against Hepatitis C Viral Protease, Helicase, ATPase, Polymerase, and Internal Ribosomal Entry Site-Mediated Translation. (1/17/2000)
NATAP Expanded Coverage of AIDS/HIV in Underserved Special Communities: African Americans, Hispanics, Women, IVDUs (1/17/2000)
Co-Infection with HBV, HCV & HDV (1/17/2000)
PUBLIC HEALTH ADVISORY FROM FDA: SAFE AND APPROPRIATE USE OF INFLUENZA DRUGS (1/17/2000)
Whites now minority of gay men with AIDS in U.S. (1/17/2000)
VIBRIO VULNIFICUS (seafood) (1/17/2000)
FATTY LIVER ---- What is fatty liver? (1/17/2000)
HBV and its Effect on HCV Therapy (1/17/2000)
Presence of Occult Hepatitis B (32% prevalence) May Reduce Response Rates to HCV Therapy, and Should Be Looked At in Future HCV Studies (1/17/2000)
Liver Fibrosis Progression in Human Immunodeficiency Virus and Hepatitis C Virus Coinfected Patients (1/17/2000)
articles from 1999 ...>